{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:29:24Z","timestamp":1783589364057,"version":"3.55.0"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"DOI":"10.12788\/cutis.1148","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:44:45Z","timestamp":1738871085000},"source":"Crossref","is-referenced-by-count":3,"title":["Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus"],"prefix":"10.12788","volume":"115","author":[{"given":"Mayra Betancourt","family":"Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/CT115001007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:44:45Z","timestamp":1738871085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/272078\/dermatologic-implications-glycemic-control-medications-patients-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.1148","relation":{},"subject":[],"published":{"date-parts":[[2025,1,1]]}}}